Provided by Tiger Fintech (Singapore) Pte. Ltd.

Iovance Biotherapeutics, Inc.

3.13
+0.03000.97%
Post-market: 3.130.00000.00%16:49 EDT
Volume:8.22M
Turnover:25.57M
Market Cap:1.03B
PE:-2.44
High:3.17
Open:3.17
Low:3.02
Close:3.10
Loading ...
Mar 11, 2021

Major Issues Report

8-K - Current report
Feb 25, 2021

Major Issues Report

8-K - Current report
Feb 25, 2021

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 16, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 16, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 12, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 10, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 09, 2021

Major Issues Report

8-K - Current report
Feb 09, 2021

Major Issues Report

8-K - Current report
Feb 01, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 29, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 11, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Jan 07, 2021

Major Issues Report

8-K - Current report
Dec 14, 2020

Major Issues Report

8-K - Current report
Nov 05, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 05, 2020

Major Issues Report

8-K - Current report
Oct 14, 2020

Major Issues Report

8-K - Current report
Oct 05, 2020

Major Issues Report

8-K - Current report
Aug 06, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 06, 2020

Major Issues Report

8-K - Current report